European Journal of Medicinal Chemistry p. 3765 - 3770 (2009)
Update date:2022-08-03
Topics:
Meppen, Malte
Pacini, Barbara
Bazzo, Renzo
Koch, Uwe
Leone, Joseph F.
Koeplinger, Kenneth A.
Rowley, Michael
Altamura, Sergio
Di Marco, Annalise
Fiore, Fabrizio
Giuliano, Claudio
Gonzalez-Paz, Odalys
Laufer, Ralph
Pucci, Vincenzo
Narjes, Frank
Gardelli, Cristina
The currently approved treatment for hepatitis C virus infections is a combination of Ribavirin and pegylated Interferon. It leads to a sustained virologic response in approximately only half of the patients treated. For this reason there is an urgent need of new therapeutic agents. 2′-C-Methylcytidine is the first nucleoside inhibitor of the HCV NS5B polymerase that was efficacious in reducing the viral load in patients infected with HCV. The application of a monophosphate prodrug approach based on unprecedented cyclic phosphoramidates is reported. Our SAR studies led to compounds that are efficiently converted to the active triphosphate in human hepatocytes.
View MoreContact:886 2 2541 0022
Address:8 Fl., No. 11, Sec. 1, Chung Shan North Rd., Taipei, Taiwan R.O.C.
FOSHAN NANHAI ZHONGNAN PHARMACEUTICAL FACTORY
Contact:0086-0757-85609331
Address:XIAHENGTIAN INDUSTRIAL ZONE,SHAYONG VILLAGE,LISHUI TOWN
Shanghai Sunwise Chemical Co., Ltd
website:http://www.sunwisechem.com
Contact:86-021-33883180
Address:Room 10E, Building G, Westlink Center, No. 2337 Gudai Road, Minhang District, Shanghai, China PC: 201100
Shanghai KFSL Pharmaceutical Technology Co.,Ltd.
Contact:+86-21-39971718
Address:859 jiadingchengliu shanghai
Jiangsu Fengshan Group Co., Ltd.
Contact:86-25-86558671
Address:1903,Central International Mansion 105-6 North Zhongshan Road, Nanjing, China
Doi:10.1007/s00706-012-0851-0
(2013)Doi:10.1039/c2cc35309a
(2012)Doi:10.1021/acs.jmedchem.0c00395
(2020)Doi:10.1016/j.tetlet.2016.06.029
(2016)Doi:10.1007/s11426-013-4925-6
(2013)Doi:10.1021/la303061r
(2012)